Table IV.
Authors/(Refs.) | Test | Treatment | Global QOL | Fatigue | Nausea and vomiting | Pain | Dyspnoea | Insomnia | Appetite loss | Constipation |
---|---|---|---|---|---|---|---|---|---|---|
Combining p-value of inverse normal methodd | 0.016 | 0.007 | <0.001 | 0.160 | 0.360 | 0.140 | 0.027 | 0.001 | ||
Rosell et al (21) | Wei Johnson test of stochastic ordering | CDDP | (0.939) | (0.955) | (0.149) | 0.971 | (0.163) | (0.985) | (0.468) | |
CBDCA | 0.042a | |||||||||
Scagliotti (22) | One-way ANOVAb | CDDP | - | 0.910 | - | - | - | 0.750 | - | |
CBDCA | 0.003a | |||||||||
Danson et al (23) | -b | CDDP | 0.992 | 0.990 | 0.998 | |||||
CBDCA | 0.015a | 0.001a | <0.001a | 0.045a | 0.001a | |||||
Paccagnella et al (24) | Repeated measure ANOVA | CDDP | (0.400) | (0.150) | (0.470) | (0.170) | ||||
CBDCA | <0.001a | 0.015a | 0.005a | 0.005a | ||||||
Rudd et al (25) | Mann-Whitney U testc | CDDP | (0.720) | 0.840 | (0.750) | (0.250) | ||||
CBDCA | 0.060a | 0.095a | 0.020a | 0.290a | ||||||
Booton et al (26) | Mann-Whitney U testb | CDDP | (0.999) | (0.999) | 0.995 | |||||
CBDCA | 0.500a | 0.009a | 0.500a | 0.500a | 0.500a |
CDDP, cisplatin; CBDCA, carboplatin; p-value, two-sided p-value. One-sided p-value could not be calculated since the direction (positive or negative) was not reported.
One-sided p-value, in favour of CBDCA.
Two-sided p-value was calculated by t-test using scores of QOL scale since the p-value of the difference from the regimens was not provided in the literature [Booton (26): two-sided p-value in nausea and vomiting was provided in the literature].
We decided whether the result was negative or positive using the median and interquartile ranges that were reported in the trial.
p<0.05 reflects a favorable outcome in CBDCA arm. Numbers in bold indicate the scale of a favorable outcome in CBDCA arm.